TABLE 1.
Pivotal Trial Efficacy Outcomes for Approved Tyrosine Kinase Inhibitors for the Treatment of GISTs 23 , 24 , 25 , 26 , 27
| Drug | Population | Overall Response Rate, % (95% CI) c | PFS, Median (95% CI), mo | OS, Median (95% CI), mo |
|---|---|---|---|---|
| Imatinib a | 1L GIST | 45 | 18 (16‐21) | 55 (47‐62) |
| Avapritinib b | PDGFRA D842V‐mutant GIST | 93 (77‐99) | NE | NE |
| Sunitinib | 2L GIST | 7 | 5.5 (2.6‐6.5) | NE |
| Regorafenib | 3L GIST | 4.5 | 4.8 (4.1‐5.8) | NR |
| Ripretinib | ≥4L GIST | 9.4 (4.2‐17.7) | 6.3 (4.6‐6.9) | 15.1 (12.3‐15.1) |
Abbreviations: CI, confidence interval; GIST, gastrointestinal stromal tumor; L, line; NE, not estimable; NR, not reported; OS, overall survival; PDGFRA, platelet‐derived growth factor receptor α; PFS, progression‐free survival.
a
Data for a 400‐mg dose once daily.
b
Data for a 300‐mg dose.
c
95% CI for overall response rate was not reported for imatinib, sunitinib, and regorafenib.